Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group study

Journal of Clinical Oncology

Volumn 25, Issue 33, 2007, Pages 5165-5171

  Burger, Robert A ^a   Sill, Michael W ^a   Monk, Bradley J ^a   Greer, Benjamin E ^a   Sorosky, Joel I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; PLATINUM; VASCULOTROPIN;

ADULT; AGED; ALLERGY; ANEMIA; ARTERY EMBOLISM; ARTERY THROMBOSIS; ARTICLE; ATRIOVENTRICULAR BLOCK; BLEEDING; BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EPITHELIUM CELL; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HEMATOLOGIC DISEASE; HUMAN; HYPERSENSITIVITY; HYPERTENSION; HYPOTENSION; ILEUS; KIDNEY DISEASE; LEUKOPENIA; LIVER DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PAIN; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; PROTHROMBIN TIME; RECURRENT CANCER; SIDE EFFECT; SINUS TACHYCARDIA; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE; VEIN EMBOLISM; VEIN THROMBOSIS; VOMITING;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 36849019301     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.5345     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006
2. Yoneda J, Kuniyasu H, Crispens MA, et al: Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 90:447-454, 1998
3. Dvorak HF: Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368-4380, 2002
4. Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77:527-543, 1999
5. Alvarez AA, Krigman HR, Whitaker RS, et al: The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res 5:587-591, 1999
6. Gasparini G, Bonoldi E, Viale G, et al: Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 69:205-211, 1996
7. Hollingsworth HC, Kohn EC, Steinberg SM, et al: Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol 147:33-41, 1995
8. Paley PJ, Staskus KA, Gebhard K, et al: Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80:98-106, 1997
9. Byrne AT, Ross L, Holash J, et al: Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 9:5721-5728, 2003
10. Gorski DH, Beckett MA, Jaskowiak NT, et al: Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374-3378, 1999
11. Hu L, Hofmann J, Zaloudek C, et al: Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161:1917-1924, 2002
12. Lee CG, Heijn M, di Tomaso E, et al: Antivascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565-5570, 2000
13. Pentecost MJ, Criqui MH, Dorros G, et al: Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels: A statement for health professionals from a special writing group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio-Thoracic and Vasc Surg, Clinical Cardiology, and Epidemiology and Prevention, the American Heart Association. Circulation 89:511-531, 1994
14. Common Terminology Criteria for Adverse Events v2.0. http://ctep.cancer. gov/reporting/ctc.html
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
16. Chen TT, Ng TH: Optimal flexible designs in phase II clinical trials. Stat Med 17:2301-2312, 1998
17. Chen H, Ye D, Xie X, et al: VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 94:630-635, 2004
18. Decaussin M, Sartelet H, Robert C, et al: Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): Correlation with angiogenesis and survival. J Pathol 188:369-377, 1999
19. Fan F, Wey JS, McCarty MF, et al: Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 24:2647-2653, 2005
20. Ferrer FA, Miller LJ, Lindquist R, et al: Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 54:567-572, 1999
21. Price DJ, Miralem T, Jiang S, et al: Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 12:129-135, 2001
22. Avastin full prescribing information: Warnings. http://www.gene.com/gene/ products/information/oncology/avastin/insert.jsp#warnings
23. Bevacizumab IND Action Letter. Bethesda, MD, Investigational Drug Branch, US Department of Health & Human Services, Cancer Therapy Evaluation Program, National Cancer Institute, 2005
24. Gordon MS, Margolin K, Talpaz M, et al: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19:843-850, 2001
25. Giantonio BJ, Catalano PJ, Meropol NJ et al: High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 23:1s, 2005 (suppl; abstr 2)
26. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
27. Sandler AB, Gray R, Brahmer J, et al: Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599. J Clin Oncol 23:2s, 2005 (suppl; abstr LBA4)
28. Miller KD: E2100: A phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 3:421-422, 2003
29. Monk BJ, Choi DC, Pugmire G, et al: Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 96:902-905, 2005
30. Numnum TM, Rocconi RP, Whitworth J, et al: The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 102:425-428, 2006
31. Monk BJ, Han E, Josephs-Cowan CA, et al: Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 102:140-144, 2006
32. Wright JD, Hagemann A, Rader JS, et al: Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer 107:83-89, 2006
33. Bidus MA, Webb JC, Seidman JD, et al: Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms. Gynecol Oncol 102:5-7, 2006
34. Cohn DE, Valmadre S, Resnick KE, et al: Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol 102:134-139, 2006